Program
Levomilnacipran
Also written as “Levomilnacipran ER”, “F2695” and “Levomilnacipran Hydrochloride Extended-Release Capsules”.
Its studies are mostly in Depressive Disorder, Major · Depression · Ischemic Stroke, led by 3 companies.
Drug pageLevomilnacipran: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVieits history only | 100 open or running | phase 4since Nov 7, 2014 | Aug 31, 2009 | none ahead |
| Pierre Fabre | 20 open or running | phase 3since Jul 10, 2012 | Jul 10, 2012 | none ahead |
| Zhejiang Huahai Pharmaceuticalits history only | 10 open or running | phase 3since Nov 18, 2025 | Nov 18, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pierre Fabre only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 10, 2012First study: phase 3 study in Ischemic StrokeFirst studyNCT01639014 · 532 enrolled · Belgium, Czech Republic, France and more
- Sep 19, 2014Phase 1 study in SubjectNCT02266966 · 17 enrolled · France
TargetBeta
“Serotonin transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Studies
All 2 Pierre Fabre leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02266966Subject · France | 1 | Completed | Sep 2014 | 17 |
| NCT01639014Ischemic Stroke · Belgium, Czech Republic, France and more | 3 | Completed | Feb 2015 | 532 |
How it is read
Names in the registry
- “Levomilnacipran ER”, 11 entries
- “F2695”, 2 entries
- “Levomilnacipran Hydrochloride Extended-Release Capsules”, 1 entry
- “Levomilnacipran”, 1 entry
- “F2695 SR”, 1 entry
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 10 studies
- Depression, 1 study
- Ischemic Stroke, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.